Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in patients with
relapsed/refractory hematological malignancies. Research is also extending to other …

Chimeric antigen receptor (CAR)-T cell therapy has shown impressive results in
chemorefractory B cell malignancies, raising the possibilities of using this …

Immunotherapy represents the fourth pillar of cancer therapy after surgery, chemotherapy,
and radiation. Chimeric antigen receptor (CAR)-T-cell therapy is an artificial immune cell …

The landscape for evidence generation in hematologic malignancies is rapidly evolving.
While randomized controlled trials (RCTs) remain the gold standard in support of drug …

Background In the past decades, highly innovative treatments in the field of diffuse large B-
cell lymphoma (DLBCL) became available in clinical practice. The aim of this study was to …

CD19-targeted chimeric antigen receptors (CAR) T cells are one of the most remarkable
cellular therapies for managing B cell malignancies. However, long-term disease-free …

Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel),
tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for …

The rationale for this project arises from some considerations. Clinical trials often use
surrogate endpoints (response rates) rather than direct measurement of benefit (survivals) …

Chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory (r/r)
large B-cell lymphoma (LBCL) is currently administered at a limited number of specialized …

Introduction CD19-directed chimeric antigen receptor T cells (CAR T) are approved for
treatment of adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL) following …